retatrutide triple agonist glp-1 gip glucagon receptor Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research

Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair

26.29

★★★★☆4.8 (126)

Retatrutide Beat Semaglutide by 7.9% in Phase 2 — Here's the Trial Data

24.47

★★★★★4.9 (98)

🚨 HOT OFF THE PRESS: Retatrutide Phase 3 data has arrived — and the obesity medicine world is paying attention. In Lilly's TRIUMPH-1 trial, participants receiving the highest dose achieved an average

24.87

★★★★★5.0 (157)

Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects

28.51

★★★★★4.7 (84)

Demonstrated metabolic effects of GIP, GLP-1 and GCG agonism as mono,

22.21

★★★★★4.9 (203)

Retatrutide 10mg Pen (1-Month Supply) Advancing the future of metabolic health Retatrutide is a next-generation therapy designed to target three key metabolic pathways—offering a more comprehensive approach to weight and glucose management

26.87

★★★★★5.0 (176)

Science Behind GLP 1 GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements

26.50

★★★★★4.8 (132)